Austar Lifesciences Limited provided consolidated earnings guidance for the year ended 31 December 2023. The group is expected to record a loss attributable to the owners of the company of approximately RMB 110 million for the year ended 31 December 2023 as compared with a profit attributable to the owners of the company of approximately RMB 87 million for the year ended 31 December 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.69 HKD | +1.47% |
|
0.00% | -55.77% |
03-26 | Austar Lifesciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
01-22 | Austar Lifesciences to Swing to Loss; Shares Drop | MT |
1st Jan change | Capi. | |
---|---|---|
-55.77% | 45.3M | |
-5.60% | 181B | |
-4.45% | 101B | |
-4.15% | 67.54B | |
-8.63% | 45.09B | |
+9.70% | 44.37B | |
+6.13% | 40.7B | |
+15.22% | 29.85B | |
+14.80% | 24.49B | |
-6.46% | 23.99B |
- Stock Market
- Equities
- 6118 Stock
- News Austar Lifesciences Limited
- Austar Lifesciences Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023